S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
NYSEAMERICAN:IGC

IGC Pharma (IGC) Stock Price, News & Analysis

$0.40
-0.01 (-1.57%)
(As of 02:24 PM ET)
Today's Range
$0.39
$0.41
50-Day Range
N/A
52-Week Range
$0.25
$0.50
Volume
278,760 shs
Average Volume
493,850 shs
Market Capitalization
$25.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IGC stock logo

About IGC Pharma Stock (NYSEAMERICAN:IGC)

IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

IGC Stock Price History

IGC Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
IGC Pharma Reports Third Quarter Fiscal 2024 Results
IGC Pharma Reports Third Quarter Fiscal 2024 Results
Why IGC Pharma Stock Is Moving Higher
IGC Pharma files for $100M mixed shelf
See More Headlines
Receive IGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/28/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:IGC
Employees
61
Year Founded
N/A

Profitability

Net Income
$-11,510,000.00
Net Margins
-1,163.24%
Pretax Margin
-1,163.24%

Debt

Sales & Book Value

Annual Sales
$910,000.00
Book Value
$0.28 per share

Miscellaneous

Free Float
51,625,000
Market Cap
$25.91 million
Optionable
Not Optionable
Beta
1.69
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Ram Mukunda (Age 65)
    President, CEO & Director
    Comp: $705k
  • Ms. Claudia Grimaldi (Age 53)
    VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director
    Comp: $245k
  • Mr. Rohit Goel (Age 30)
    Senior Director of Accounting & Principal Accounting Officer

IGC Stock Analysis - Frequently Asked Questions

How have IGC shares performed in 2024?

IGC Pharma's stock was trading at $0.3446 at the start of the year. Since then, IGC stock has increased by 19.9% and is now trading at $0.4131.
View the best growth stocks for 2024 here
.

Are investors shorting IGC Pharma?

IGC Pharma saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 848,500 shares, a drop of 6.8% from the February 29th total of 910,700 shares. Based on an average trading volume of 471,200 shares, the days-to-cover ratio is currently 1.8 days.
View IGC Pharma's Short Interest
.

How were IGC Pharma's earnings last quarter?

IGC Pharma, Inc. (NYSEAMERICAN:IGC) issued its earnings results on Wednesday, February, 14th. The construction company reported ($0.09) earnings per share (EPS) for the quarter. The construction company had revenue of $0.20 million for the quarter. IGC Pharma had a negative trailing twelve-month return on equity of 110.37% and a negative net margin of 1,163.24%.

What other stocks do shareholders of IGC Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IGC Pharma investors own include GW Pharmaceuticals (GWPH), Alibaba Group (BABA), Tilray (TLRY), Cronos Group (CRON), Micron Technology (MU), NewAge (NBEV), Advanced Micro Devices (AMD), Ford Motor (F) and NIO (NIO).

Who are IGC Pharma's major shareholders?

IGC Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of IGC Pharma?

Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:IGC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners